CYP4F3B expression is associated with differentiation of HepaRG human hepatocytes and unaffected by fatty acid overload

Drug Metabolism and Disposition

Volumn 39, Issue 10, 2011, Pages 1987-1996

  Madec, Stéphanie ^a   Cerec, Virginie ^b,c   Plée Gautier, Emmanuelle ^d   Antoun, Joseph ^d   Glaise, Denise ^b,c   Salaun, Jean Pierre ^a,d   Guguen Guillouzo, Christiane ^b,c   Corlu, Anne ^b,c  

^a CNRS   (France)

^b INSERM   (France)

^c UNIVERSITÉ DE RENNES 1   (France)

^d FACULTÉ DE MÉDECINE ET DES SCIENCES DE LA SANTÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

18 HYDROXY 9(10) EPOXYSTEARIC ACID; 9(10) EPOXYSTEARIC ACID; CYTOCHROME P450; CYTOCHROME P450 4A11; CYTOCHROME P450 4F12; CYTOCHROME P450 4F2; CYTOCHROME P450 4F3B; DOCOSAHEXAENOIC ACID; FATTY ACID; FATTY ACID SYNTHASE; MONOUNSATURATED FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; POLYUNSATURATED FATTY ACID; SATURATED FATTY ACID; STEARIC ACID DERIVATIVE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; UNCLASSIFIED DRUG;

ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; CYP4F3 GENE; DOWN REGULATION; ENERGY METABOLISM; ENZYME SUBSTRATE; GENE; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; HYDROXYLATION; LIPID METABOLISM; LIPOGENESIS; LIVER CELL; LIVER MICROSOME; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEATOSIS; UPREGULATION;

ALTERNATIVE SPLICING; CELL DIFFERENTIATION; CELL LINE; CYTOCHROME P-450 ENZYME SYSTEM; DOCOSAHEXAENOIC ACIDS; FATTY ACID SYNTHETASE COMPLEX; FATTY ACIDS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEPATOCYTES; HUMANS; HYDROXYLATION; LIPID METABOLISM; LIPOGENESIS; LIVER; MICROSOMES, LIVER; PPAR ALPHA; PPAR GAMMA; PROTEIN ISOFORMS; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

EID: 80053139529     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.036848     Document Type: Article

References (39)

1. Aninat C, Piton A, Glaise D, Le Charpentier T, Langouët S, Morel F, Guguen-Guillouzo C, and Guillouzo A (2006) Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab Dispos 34:75-83. (Pubitemid 43042648)
2. Antoun J, Amet Y, Simon B, Dréano Y, Corlu A, Corcos L, Salaun JP, and Plée-Gautier E (2006) CYP4A11 is repressed by retinoic acid in human liver cells. FEBS Lett 580:3361-3367. (Pubitemid 43810238)
3. Antoun J, Goulitquer S, Amet Y, Dreano Y, Salaun JP, Corcos L, and Plée-Gautier E (2008) CYP4F3B is induced by PGA1 in human liver cells: a regulation of the 20-HETE synthesis. J Lipid Res 49:2135-2141.
4. Berthou F, Ratanasavanh D, Riche C, Picart D, Voirin T, and Guillouzo A (1989) Comparison of caffeine metabolism by slices, microsomes and hepatocyte cultures from adult human liver. Xenobiotica 19:401-417. (Pubitemid 19108258)
5. Capdevila JH, Mosset P, Yadagiri P, Lumin S, and Falck JR (1988) NADPH-dependent microsomal metabolism of 14,15-epoxyeicosatrienoic acid to diepoxides and epoxyalcohols. Arch Biochem Biophys 261:122-133. (Pubitemid 18070786)
6. Cerec V, Glaise D, Garnier D, Morosan S, Turlin B, Drenou B, Gripon P, Kremsdorf D, Guguen-Guillouzo C, and Corlu A (2007) Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor. Hepatology 45:957-967. (Pubitemid 46631564)
7. Christmas P, Jones JP, Patten CJ, Rock DA, Zheng Y, Cheng SM, Weber BM, Carlesso N, Scadden DT, Rettie AE, et al. (2001) Alternative splicing determines the function of CYP4F3 by switching substrate specificity. J Biol Chem 276:38166-38172.
8. Christmas P, Carlesso N, Shang H, Cheng SM, Weber BM, Preffer FI, Scadden DT, and Soberman RJ (2003) Myeloid expression of cytochrome P450 4F3 is determined by a lineage-specific alternative promoter. J Biol Chem 278:25133-25142. (Pubitemid 37548677)
9. De Gottardi A, Vinciguerra M, Sgroi A, Moukil M, Ravier-Dall'Antonia F, Pazienza V, Pugnale P, Foti M, and Hadengue A (2007) Microarray analyses and molecular profiling of steatosis induction in immortalized human hepatocytes. Lab Invest 87:792-806. (Pubitemid 47077255)
10. Dickins M (2004) Induction of cytochromes P450. Curr Top Med Chem 4:1745-1766.
11. Fabbrini E, Sullivan S, and Klein S (2010) Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 51:679-689.
12. Fer M, Corcos L, Dréano Y, Plée-Gautier E, Salaün JP, Berthou F, and Amet Y (2008) Cytochromes P450 from family 4 are the main omega hydroxylating enzymes in humans: CYP4F3B is the prominent player in PUFA metabolism. J Lipid Res 49:2379-2389.
13. French SW, Morimoto M, Reitz RC, Koop D, Klopfenstein B, Estes K, Clot P, Ingelman-Sundberg M, and Albano E (1997) Lipid peroxidation, CYP2E1 and arachidonic acid metabolism in alcoholic liver disease in rats. J Nutr 127:907S-911S. (Pubitemid 27209466)
14. Goetzl EJ, An S, and Smith WL (1995) Specificity of expression and effects of eicosanoid mediators in normal physiology and human diseases. FASEB J 9:1051-1058.
15. Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, Cannie I, Guyomard C, Lucas J, Trepo C, and Guguen-Guillouzo C (2002) Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci USA 99:15655-15660. (Pubitemid 35403987)
16. Hardwick JP (2008) Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases. Biochem Pharmacol 75:2263-2275.
17. Hardwick JP, Osei-Hyiaman D, Wiland H, Abdelmegeed MA, and Song BJ (2009) PPAR/RXR regulation of fatty acid metabolism and fatty acid omega-hydroxylase (CYP4) isozymes: implications for prevention of lipotoxicity in fatty liver disease. PPAR Res 2009:952734.
18. Hsu MH, Savas U, Griffin KJ, and Johnson EF (2007) Human cytochrome p450 family 4 enzymes: function, genetic variation and regulation. Drug Metab Rev 39:515-538. (Pubitemid 47355735)
19. Hwang-Verslues WW and Sladek FM (2010) HNF4≲αλπη α∀-role in drug metabolism and potential dug target? Curr Opin Pharmacol 10:698-705.
20. Isom HC, Secott T, Georgoff I, Woodworth C, and Mummaw J (1985) Maintenance of differentiated rat hepatocytes in primary culture. Proc Natl Acad Sci USA 82:3252-3256. (Pubitemid 15033161)
21. Kalsotra A and Strobel HW (2006) Cytochrome P450 4F subfamily: at the crossroads of ecosanoid and drug metabolism. Pharmacol Ther 112:589-611. (Pubitemid 44573491)
22. Kikuta Y, Kusunose E, Kondo T, Yamamoto S, Kinoshita H, and Kusunose M (1994) Cloning and expression of a novel form of leukotriene B4 omega-hydroxylase from human liver. FEBS Lett 348:70-74. (Pubitemid 24223036)
23. Kris-Etherton PM, Harris WS, Appel LJ, and American Heart Association. Nutrition Committee (2002) Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 106:2747-2757. (Pubitemid 35364932)
24. Lambert CB, Spire C, Claude N, and Guillouzo A (2009) Dose- and time-dependent effects of phenobarbital on gene expression profiling in human hepatoma HepaRG cells. Toxicol Appl Pharmacol 234:345-360.
25. Larter CZ, Chitturi S, Heydet D, and Farrell GC (2010) A fresh look at NASH pathogenesis. Part 1: the metabolic movers. J Gastroenterol Hepatol 25:672-690.
26. Le Quéré V, Plée-Gautier E, Potin P, Madec S, and Salaün JP (2004) Human CYP4F3s are the main catalysts in the oxidation of fatty acid epoxides. J Lipid Res 45:1446-1458.
27. Le Vee M, Jigorel E, Glaise D, Gripon P, Guguen-Guillouzo C, and Fardel O (2006) Functional expression of sinusoidal and canalicular hepatic drug transporters in the differentiated human hepatoma HepaRG cell line. Eur J Pharm Sci 28:109-117.
28. Mater MK, Thelen AP, Pan DA, and Jump DB (1999) Sterol response element-binding protein 1c (SREBP-1c) is involved in the polyunsaturated fatty acid suppression of hepatic S14 gene transcription. J Biol Chem 274:32725-32732. (Pubitemid 129535302)
29. Nelson DR, Zeldin DC, Hoffman SM, Maltais LJ, Wain HM, and Nebert DW (2004) Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 14:1-18. (Pubitemid 38183957)
30. Ou J, Tu H, Shan B, Luk A, DeBose-Boyd RA, Bashmakov Y, Goldstein JL, and Brown MS (2001) Unsaturated fatty acids inhibit transcription of the sterol regulatory element-binding protein-1c (SREBP-1c) gene by antagonizing ligand-dependent activation of the LXR. Proc Natl Acad Sci USA 98:6027-6032. (Pubitemid 32488187)
31. Petrescu AD, Hertz R, Bar-Tana J, Schroeder F, and Kier AB (2002) Ligand specificity and conformational dependence of the hepatic nuclear factor-4alpha (HNF-4alpha). J Biol Chem 277:23988-23999. (Pubitemid 34951910)
32. Ren B, Thelen AP, Peters JM, Gonzalez FJ, and Jump DB (1997) Polyunsaturated fatty acid suppression of hepatic fatty acid synthase and S14 gene expression does not require peroxisome proliferator-activated receptor α. J Biol Chem 272:26827-26832. (Pubitemid 27452629)
33. Sanders RJ, Ofman R, Duran M, Kemp S, and Wanders RJ (2006) Omega-oxidation of very long-chain fatty acids in human liver microsomes. Implications for X-linked adrenoleukodystrophy. J Biol Chem 281:13180-13187. (Pubitemid 43855229)
34. Savas U, Hsu MH, and Johnson EF (2003) Differential regulation of human CYP4A genes by peroxisome proliferators and dexamethasone. Arch Biochem Biophys 409:212-220. (Pubitemid 36042918)
35. Savas U, Machemer DE, Hsu MH, Gaynor P, Lasker JM, Tukey RH, and Johnson EF (2009) Opposing roles of peroxisome proliferator-activated receptor alpha and growth hormone in the regulation of CYP4A11 expression in a transgenic mouse model. J Biol Chem. 284:16541-16552.
36. Yuan X, Ta TC, Lin M, Evans JR, Dong Y, Bolotin E, Sherman MA, Forman BM, and Sladek FM (2009) Identification of an endogenous ligand bound to a native orphan nuclear receptor. PLoS One 4:e5609.
37. Zhang X, Chen L, and Hardwick JP (2000) Promoter activity and regulation of the CYP4F2 leukotriene B(4) omega-hydroxylase gene by peroxisomal proliferators and retinoic acid in HepG2 cells. Arch Biochem Biophys 378:364-376. (Pubitemid 30397637)
38. Zheng J, Plopper CG, Lakritz J, Storms DH, and Hammock BD (2001) Leukotoxin-diol: a putative toxic mediator involved in acute respiratory distress syndrome. Am J Respir Cell Mol Biol 25:434-438. (Pubitemid 33037675)
39. Zheng X, Rivabene R, Cavallari C, Napolitano M, Avella M, Bravo E, and Botham KM (2002) The effects of chylomicron remnants enriched in n-3 or n-6 polyunsaturated fatty acids on the transcription of genes regulating their uptake and metabolism by the liver: influence of cellular oxidative state. Free Radic Biol Med 32:1123-1131. (Pubitemid 34603350)